William Gann (@gann_will) 's Twitter Profile
William Gann

@gann_will

Psychiatrist in Sheffield, UK. Eating disorders. Neuroscience education. Clinical drug trials in mental health. Psychedelic treatments.

ID: 981564388510523392

calendar_today04-04-2018 16:09:21

165 Tweet

223 Followers

442 Following

William Gann (@gann_will) 's Twitter Profile Photo

Great day RCPsych Eating Disorders Faculty conference. Extremely proud of the work Bethan Holdsworth is presenting here on the perspectives of ED sufferers on #psychedelics. Many thanks to Ellie Wildbore too... strong #PPI vibes all day.

Great day <a href="/rcpsychEDFac/">RCPsych Eating Disorders Faculty</a> conference.  Extremely proud of the work Bethan Holdsworth is presenting here on the perspectives of ED sufferers on #psychedelics. Many thanks to <a href="/EllieWildbore/">Ellie Wildbore</a> too... strong #PPI vibes all day.
William Gann (@gann_will) 's Twitter Profile Photo

Oh my goodness, we won first prize!!! Huge kudos to Bethan who has worked so hard on this project. So important that we listen carefully to our patients as we slowly edge forward in the #psychedelic field. Ellie Wildbore Sheffield Health and Social Care NHS FT Watch this space for the final write up.

Mitchell B. Slapik (@mslapik) 's Twitter Profile Photo

According to dynamical systems, psychiatric disorders can be seen as energy landscapes with peaks and valleys. OCD has deep valleys where neural activity gets stuck, while schizophrenia has shallow valleys that let neural activity roam too freely, connecting unrelated ideas.

William Gann (@gann_will) 's Twitter Profile Photo

Why are we not prioritising intercalated degrees for med students? We are going to lose something important here. 'Doctor as scholar' is 1st outcome? GMC

William Gann (@gann_will) 's Twitter Profile Photo

Investigator's meeting in Prague with Compass Pathways Guy Goodwin talking about how our study protocol addresses important concerns about placebo/unblinding.

Investigator's meeting in Prague with <a href="/COMPASSPathway/">Compass Pathways</a> 
Guy Goodwin talking about how our study protocol addresses important concerns about placebo/unblinding.
William Gann (@gann_will) 's Twitter Profile Photo

Some more big news from GH Research yesterday. n=81 phase 2b in TRD. 57.5% in remission at day 8! After a 15minute psychedelic experience with good medical care but no formal therapy. 77.8% getting to remission with repeat dosing. Game changing?! investor.ghres.com/news-releases/…

William Gann (@gann_will) 's Twitter Profile Photo

Are we excited about psychedelics because we are excited about psychedelics, or are we projecting our dreams onto this field from a place of deep dissatisfaction with existing psychiatry? youtu.be/DV5R9tM4LFw?si…